Trials / Conditions / BRAF V600E Mutation Present
BRAF V600E Mutation Present
4 registered clinical trials studyying BRAF V600E Mutation Present.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refract NCT04061980 | Providence Health & Services | Phase 2 |
| Active Not Recruiting | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma NCT03224767 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Terminated | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are NCT02097225 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is NCT01940809 | National Cancer Institute (NCI) | Phase 1 |